181 related articles for article (PubMed ID: 25724491)
1. Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.
Clay SA; Domeier TL; Hanft LM; McDonald KS; Krenz M
Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1086-95. PubMed ID: 25724491
[TBL] [Abstract][Full Text] [Related]
2. Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.
Roy R; Krenz M
J Mol Cell Cardiol; 2017 Nov; 112():83-90. PubMed ID: 28911943
[TBL] [Abstract][Full Text] [Related]
3. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
Schramm C; Fine DM; Edwards MA; Reeb AN; Krenz M
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H231-43. PubMed ID: 22058153
[TBL] [Abstract][Full Text] [Related]
4. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
[TBL] [Abstract][Full Text] [Related]
5. The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
Edwards MA; Crombie K; Schramm C; Krenz M
J Appl Physiol (1985); 2015 Jan; 118(1):124-31. PubMed ID: 25359717
[TBL] [Abstract][Full Text] [Related]
6. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
[TBL] [Abstract][Full Text] [Related]
7. Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines.
Yi JS; Perla S; Enyenihi L; Bennett AM
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584792
[TBL] [Abstract][Full Text] [Related]
8. Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
Lauriol J; Cabrera JR; Roy A; Keith K; Hough SM; Damilano F; Wang B; Segarra GC; Flessa ME; Miller LE; Das S; Bronson R; Lee KH; Kontaridis MI
J Clin Invest; 2016 Aug; 126(8):2989-3005. PubMed ID: 27348588
[TBL] [Abstract][Full Text] [Related]
9. Dilated cardiomyopathy mutations in thin-filament regulatory proteins reduce contractility, suppress systolic Ca
Robinson P; Sparrow AJ; Patel S; Malinowska M; Reilly SN; Zhang YH; Casadei B; Watkins H; Redwood C
Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H306-H319. PubMed ID: 32618513
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models.
Ferrantini C; Coppini R; Pioner JM; Gentile F; Tosi B; Mazzoni L; Scellini B; Piroddi N; Laurino A; Santini L; Spinelli V; Sacconi L; De Tombe P; Moore R; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Tesi C; Poggesi C
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28735292
[TBL] [Abstract][Full Text] [Related]
11. SERCA Cys674 sulphonylation and inhibition of L-type Ca2+ influx contribute to cardiac dysfunction in endotoxemic mice, independent of cGMP synthesis.
Hobai IA; Buys ES; Morse JC; Edgecomb J; Weiss EH; Armoundas AA; Hou X; Khandelwal AR; Siwik DA; Brouckaert P; Cohen RA; Colucci WS
Am J Physiol Heart Circ Physiol; 2013 Oct; 305(8):H1189-200. PubMed ID: 23934853
[TBL] [Abstract][Full Text] [Related]
12. Hypertrophic cardiomyopathy mutations increase myofilament Ca
Robinson P; Liu X; Sparrow A; Patel S; Zhang YH; Casadei B; Watkins H; Redwood C
J Biol Chem; 2018 Jul; 293(27):10487-10499. PubMed ID: 29760186
[TBL] [Abstract][Full Text] [Related]
13. Modulation of SR Ca2+ release by the triadin-to-calsequestrin ratio in ventricular myocytes.
Kučerová D; Baba HA; Bokník P; Fabritz L; Heinick A; Mát'uš M; Müller FU; Neumann J; Schmitz W; Kirchhefer U
Am J Physiol Heart Circ Physiol; 2012 May; 302(10):H2008-17. PubMed ID: 22427521
[TBL] [Abstract][Full Text] [Related]
14. Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines.
Yi JS; Perla S; Huang Y; Mizuno K; Giordano FJ; Vinks AA; Bennett AM
Cardiovasc Drugs Ther; 2022 Aug; 36(4):589-604. PubMed ID: 33689087
[TBL] [Abstract][Full Text] [Related]
15. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
[TBL] [Abstract][Full Text] [Related]
16. Induced overexpression of phospholemman S68E mutant improves cardiac contractility and mortality after ischemia-reperfusion.
Wang J; Song J; Gao E; Zhang XQ; Gu T; Yu D; Koch WJ; Feldman AM; Cheung JY
Am J Physiol Heart Circ Physiol; 2014 Apr; 306(7):H1066-77. PubMed ID: 24486513
[TBL] [Abstract][Full Text] [Related]
17. Peptidyl-Prolyl Isomerase 1 Regulates Ca
Sacchi V; Wang BJ; Kubli D; Martinez AS; Jin JK; Alvarez R; Hariharan N; Glembotski C; Uchida T; Malter JS; Yang Y; Gross P; Zhang C; Houser S; Rota M; Sussman MA
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29018025
[TBL] [Abstract][Full Text] [Related]
18. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
Schramm C; Edwards MA; Krenz M
J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
[TBL] [Abstract][Full Text] [Related]
19. Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog.
Hahn A; Lauriol J; Thul J; Behnke-Hall K; Logeswaran T; Schänzer A; Böğürcü N; Garvalov BK; Zenker M; Gelb BD; von Gerlach S; Kandolf R; Kontaridis MI; Schranz D
Am J Med Genet A; 2015 Apr; 167A(4):744-51. PubMed ID: 25708222
[TBL] [Abstract][Full Text] [Related]
20. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
